Ann: Top 20 securityholders, page-67

Agree with a lot of what you say CBD.   I believe we are in a very different position than years ago. But lifting the legal did not set us free from a sp perspective.  I am one who believes management need to deliver before the market faith will rise. And I seriously hope you are 1000% wrong and that we get more than one crack, because we have already had a crack at the US and couldn't get traction.  Timing with US pharma sector in a bit of change was part but not all of it imo.  The US was our prime market then we abandoned that and really seemed to lose hold of the tiller for a few years, we moved into presenting Asia and South America as our primary markets.  Of course you'd have to say that so that we looked like something was on-track.  Last year, we decided the US was our market, like we had just discovered it.  Our first "crack" was not successful in the US.  So, I do hope we get more than one crack.
And I certainly hope our presentations aren't the be-all because, quite frankly, we s*** at getting our announcements and presentations right, even at the most critical times.  Yes, we are *still* learning on the job and my personal opinion is that we could have done a lot better if we had had more experienced and skilled people in the right positions.  However, that doesn't add anything because we are where we are and I hope this time we get wings instead of lead boots.  The product has potential BUT we still haven't seen any results proving that  it works.  IMO until we see those proofs, we won't have the big pharmas on any more than research partnerships and won't close those deals that will set the market on fire.  So.... I'm waiting for the research and testing to bring us a result that launches this puppy.  Not holding my breath on management, we still see them making mistakes, it is my personal opinion we have had the wrong people in the right jobs and it has cost us.  But I do believe the product might have what it takes. 
Anagrelide...?  The challenges there are astronomical and that is why we didn't pay anything to pick it up.  Results....?  a decade or more away and (like malaria) who knows where research and cures will be at that point.  So it bothers me that this is apparently the big selling point of the company.
As for sp, well you can argue up and down on that.  The sp is not a reliable reflection of a company, but then again it can be.  So... we wait and the rampers come and the rampers go, and the stale get more stale and we wait..... C'mon lab, give us something we can take to the bank.  With dead cat bounces and such low market believe, no doubt we will continue to slide or bump along the bottom until then.